These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 18852398)

  • 21. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.
    Marrs JC
    Drugs Aging; 2012 May; 29(5):e1-e12. PubMed ID: 22530704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes.
    Younk LM; Davis SN
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):515-25. PubMed ID: 22432790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.
    Vega GL; Dunn FL; Grundy SM
    Am J Cardiol; 2011 Oct; 108(8):1129-35. PubMed ID: 21813109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
    Ooi CP; Loke SC
    Diabet Med; 2014 Jan; 31(1):2-14. PubMed ID: 24024701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of colesevelam HCl in type 2 diabetes mellitus therapy.
    Handelsman Y
    Postgrad Med; 2009 May; 121(3 Suppl 1):19-24. PubMed ID: 19494474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.
    Rosenstock J; Hernandez-Triana E; Handelsman Y; Misir S; Jones MR
    Postgrad Med; 2012 Jul; 124(4):14-20. PubMed ID: 22913890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
    Elkeles RS
    Diabet Med; 2014 Jul; 31(7):880. PubMed ID: 24588426
    [No Abstract]   [Full Text] [Related]  

  • 31. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.
    Bays HE; Cohen DE
    Curr Med Res Opin; 2007 Jul; 23(7):1673-84. PubMed ID: 17588297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia.
    Dayer-Berenson L; Finckenor M
    Postgrad Med; 2014 May; 126(3):126-34. PubMed ID: 24918798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus.
    Staels B
    Postgrad Med; 2009 May; 121(3 Suppl 1):25-30. PubMed ID: 19494475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of colesevelam HCl in the treatment of elderly patients.
    Gavin JR; Jones MR; Ford DM; Truitt KE
    Drugs Aging; 2014 Jun; 31(6):461-70. PubMed ID: 24777691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colesevelam for type 2 diabetes mellitus.
    Ooi CP; Loke SC
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD009361. PubMed ID: 23235674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.